References

All references link to appropriate papers

1.

EMC. Xromi 100 mg/ml oral solution – Summary Of Product Characteristics (SmPC) [Internet] 2019. Available from: https://www.medicines.org.uk/emc/product/10549 Accessed March 2024

2.

Batchelor HK, Marriott JF. Formulations for children: Problems and solutions. Br J Clin Pharmacol. 2015;79(3):405–18.

3.

Ferster A, Vermylen C, Cornu G, Buyse M, Corazza F, Devalck C, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood.1996;88(6):1960–4.

4.

Qureshi A, Kaya B, Pancham S, Keenan R, Anderson J, Akanni M, et al. Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: A British Society for Haematology Guideline. Br J Haematol. 2018;181(4):460–75.

5.

Agrawal RK, Patel RK, Shah V, Nainiwa L, Trivedi B. Hydroxyurea in sickle cell disease: Drug Review. Indian J Hematol Blood Transfus. 2014;30(2):91–6.

6.

Guy’s and St Thomas’ NHS Foundation Trust. Hydroxycarbamide for children with sickle cell disease. [online] May 2020. Available at: https://link.edgepilot.com/s/8dea1680/ovTWGyqXU0Oig-zyZCr5MA?u=https://www.evelinalondon.nhs.uk/our-services/hospital/sickle-cell-and-thalassaemia/patient-leaflets.aspx Accessed March 2024

7.

Hankins JS, McCarville MB, Rankine-Mullings A, Reid ME, Lobo CLC, Moura PG, et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial. Am J Hematol. 2015 Dec 1;90(12):1099–105.

8.

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood.2005;106(7):2269–75.

9.

Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001;139(6):790–6.

10.

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia – TCD with Transfusions Changing to Hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–70.

11.

Lopes de Castro Lobo C, Pinto JFC, Nascimento EM, Moura PG, Cardoso GP, Hankins JS. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol. 2013;161(6):852–60.

12.

Ward J, Lewis N, Tsitsikas DA. Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea BMJ Quality Improvement Report. BMJ Open Qual. 2018;7:e218.

13.

Charache S, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317-22.

14.

EMA Formulations of choice for the paediatric population [Internet] 2006. Available from: https://www.ema.europa.eu/en/formulations-choice-paediatric-population#document-history—first-version-(current)-section Accessed March 2024

15.

Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv. 2007;4(1):37–45.